Citius Pharmaceuticals (CTXR) Price & Analysis

Compare

1,745 Followers

CTXR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.65 - $13.52

Previous CloseN/A

Volume111.57K

Average Volume (3M)403.99K

Market Cap

$19.56M

Enterprise Value$15.80M

Total Cash (Recent Filing)$26.41K

Total Debt (Recent Filing)$931.79K

Price to Earnings (P/E)―

Beta1.78

Next Earnings

Feb 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.80

Shares Outstanding17,012,192

10 Day Avg. Volume264,687

30 Day Avg. Volume403,990

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.81

Enterprise Value/Revenue101.30

Enterprise Value/Gross Profit-96.50

Enterprise Value/Ebitda-0.37

Forecast

1Y Price Target

$6.00

Price Target Upside421.74% Upside

Rating ConsensusHold

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe company reported positive top-line data from the P3 study, achieving its primary endpoint of increase in time to catheter failure.

Commercialization PotentialCitius has achieved a critical milestone in future Lymphir commercialization and patient support with the assignment of a unique, permanent HCPCS J-code by the CMS.

Regulatory GuidanceThe FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.

Bears Say

Capital RequirementsCitius Pharma needs to secure additional capital prior to a launch of Lymphir.

Financial ConstraintsThe company's recent quarterly report suggests the need for additional capital in the immediate future to support operations.

Regulatory Approval TimelineCompleting the steps remaining in Mino-Lok’s pathway to regulatory approval could take some time, leading to a forecasted launch in mid-2026 instead of early 2026.

Citius Pharmaceuticals News

Citius Oncology announces pricing of $9M registered direct offering

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced that it has entered into a securities...

20d ago

CTOR

CTXR

Citius Pharma Reports Q2 2025 Financial Results

Citius Pharma ( ($CTXR) ) has released its Q3 earnings. Here is a breakdown of the information Citius...

1M ago

CTXR

Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last year

As of June 30 the Company had $112 in cash and cash equivalents and 71,552,402 common shares outstanding....

2M ago

CTXR

Citius Oncology signs distribution agreement for Lymphir with Cencora

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), executed a distribution services agreement with Cencora –...

3M ago

CTOR

CTXR

Citius Pharmaceuticals Regains Nasdaq Compliance

Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On July 8, 2025, Citius Pharmaceuticals announced that it...

3M ago

CTXR

Citius Oncology expects commercial launch of Lymphir in second half of 2025

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced that preparations for the commercial launch of...

3M ago

CTOR

CTXR

Citius Pharmaceuticals Closes $6M Securities Offering

An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On June 9, 2025, Citius Pharmaceuticals entered...

4M ago

CTXR

Citius Pharmaceuticals price target lowered to $6 from $9 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on Citius Pharmaceuticals (CTXR) to $6 from $9 and keeps...

4M ago

CTXR

Citius Pharmaceuticals announces $15.8M registered direct offering

Citius Pharmaceuticals (CTXR) announced that it has entered into definitive agreements for the purchase of an aggregate of...

4M ago

CTXR

Citius Pharmaceuticals Expands Authorized Shares Significantly

Citius Pharmaceuticals ( ($CTXR) ) just unveiled an update. On June 9, 2025, Citius Pharmaceuticals filed a Certificate...

4M ago

CTXR

Citius Oncology enters distribution services agreement with Cardinal Health

Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals,(CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical...

4M ago

CAH

CTOR

Citius Pharmaceuticals Issues $1M Promissory Note to Pagoda

Citius Pharmaceuticals ( ($CTXR) ) just unveiled an announcement. On June 2, 2025, Citius Pharmaceuticals issued a $1...

4M ago

CTXR

Citius Pharmaceuticals downgraded to Hold from Buy at Maxim

Maxim downgraded Citius Pharmaceuticals (CTXR) to Hold from Buy. Published first on TheFly – the ultimate source for...

4M ago

CTXR

Citius Pharmaceuticals Reports Q1 2025 Earnings and Strategic Developments

Citius Pharma ( ($CTXR) ) has released its Q2 earnings. Here is a breakdown of the information Citius...

5M ago

CTXR

CTXR FAQ

What was Citius Pharmaceuticals’s price range in the past 12 months?

Citius Pharmaceuticals lowest stock price was $0.65 and its highest was $13.52 in the past 12 months.

What is Citius Pharmaceuticals’s market cap?

Citius Pharmaceuticals’s market cap is $19.56M.

When is Citius Pharmaceuticals’s upcoming earnings report date?

Citius Pharmaceuticals’s upcoming earnings report date is Feb 06, 2026 which is in 129 days.

How were Citius Pharmaceuticals’s earnings last quarter?

Citius Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.505 by -$0.295.

Is Citius Pharmaceuticals overvalued?

According to Wall Street analysts Citius Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Citius Pharmaceuticals pay dividends?

Citius Pharmaceuticals does not currently pay dividends.

What is Citius Pharmaceuticals’s EPS estimate?

Citius Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Citius Pharmaceuticals have?

Citius Pharmaceuticals has 17,012,192 shares outstanding.

What happened to Citius Pharmaceuticals’s price movement after its last earnings report?

Citius Pharmaceuticals reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.505. Following the earnings report the stock price went down -1.538%.

Which hedge fund is a major shareholder of Citius Pharmaceuticals?

Currently, no hedge funds are holding shares in CTXR

Citius Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-53.42%

Trailing 12-Months

Asset Growth

31.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. (CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care, prescription products, and unique therapies using innovative delivery mechanisms. The company operates primarily in the biotechnology and healthcare sectors, leveraging its expertise to address unmet medical needs by developing and enhancing existing drug formulations.

Citius Pharmaceuticals (CTXR) Earnings & Revenues

Historic Earnings Reports

CTXR Stock 12 Month Forecast

Average Price Target

$6.00

▲(421.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","11":"$11","17":"$17","23":"$23","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,5,11,17,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.29,1.6523076923076925,2.014615384615385,2.376923076923077,2.7392307692307694,3.101538461538462,3.463846153846154,3.8261538461538462,4.188461538461539,4.550769230769231,4.913076923076924,5.275384615384615,5.637692307692308,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.29,1.6523076923076925,2.014615384615385,2.376923076923077,2.7392307692307694,3.101538461538462,3.463846153846154,3.8261538461538462,4.188461538461539,4.550769230769231,4.913076923076924,5.275384615384615,5.637692307692308,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.29,1.6523076923076925,2.014615384615385,2.376923076923077,2.7392307692307694,3.101538461538462,3.463846153846154,3.8261538461538462,4.188461538461539,4.550769230769231,4.913076923076924,5.275384615384615,5.637692307692308,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.92,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.44,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.58,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.64,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >